The long-term goal of this project is to understand how natural killer T (NKT) cells recognize and respond to microorganisms in the respiratory mucosa. We have previously shown that NKT cells in the lungs play a critical role in the development of airway inflammation and asthma. In addition, we have shown that glycolipids from the bacterial species Sphingomonas can directly activate pulmonary NKT cells in mice and induce airway inflammation and airway hyperreactivity (AHR), a cardinal feature of asthma. These results suggest that NKT cells in the lung mucosa may respond to other microorganisms that enter the lung, and that NKT cells could play a previously unsuspected critical role in regulating pulmonary mucosal immune responses. Although only a few microorganisms are known to activate NKT cells, based on strong preliminary data, we believe that many pulmonary microorganisms, including Streptococcus pneumoniae, Burkholderia cenocepacia, Sphingomonas paucimobilis and Aspergillus fumigatus express glycolipids that can activate NKT cells, resulting in innate and adaptive mucosal immune responses. Furthermore, we hypothesize that microorganisms such as Sphingomonas paucimobilis, are much more common in the airway mucosa of patients with chronic pulmonary inflammatory diseases than previously recognized, and that host responses to these previously unrecognized microorganisms in the endobronchial mucosa can trigger chronic diseases in the airways. We therefore propose to identify glycolipids from S. pneumoniae, B. cenocepacia, and A. fumigatus that can directly activate NKT cells, thus demonstrating a specific mechanism by which these microorganisms can activate NKT cells and induce AHR, inflammation and asthma. Further, to demonstrate the clinical relevance of such mechanisms, we propose to examine the lungs of patients with chronic lung disease (e.g., asthma) for the presence of bacteria, using an extremely sensitive, novel non-culture based 16S rRNA PhyloChip microarray method, which uses approximately 500,000 probes to detect the 16S ribosomal RNA signatures from 9,000 bacteria. Surprisingly, preliminary data indicate that a highly diverse complex bacterial consortia, including S. pneumoniae, and bacteria not previously detected by cultured based techniques, such as Sphingomonas species (expressing glycolipids that can activate NKT cells), are indeed present in the lungs of a large fraction of patients with asthma. We have assembled an outstanding team of investigators, including experts in lung biology, lipid biochemistry, microbiology and immunology. Using very novel techniques, we have generated exciting preliminary data, which suggest that our studies will greatly expand the fundamental understanding of the types of immune responses that develop against microorganisms present in the respiratory mucosa, and how these responses result in the development of chronic lung diseases, such as asthma.

Public Health Relevance

The results of these studies will have a direct impact on our fundamental understanding of the immune responses that occur in the respiratory mucosa. We propose to understand how a novel cell type, called natural killer T cells, fundamentally regulates innate and adaptive immunity to respiratory microorganisms. In addition, using a novel, highly sensitive non-culture molecular method, we will define the microorganisms that are present in the lungs of patients with chronic lung disease, such as asthma. These results will provide a much greater appreciation and understanding of mucosal immunity to microorganisms present in the respiratory tract, and how these immune responses lead to respiratory inflammation and to the development of chronic lung diseases, such as asthma and COPD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI083523-01
Application #
7706862
Study Section
Special Emphasis Panel (ZAI1-PTM-I (M2))
Program Officer
Rothermel, Annette L
Project Start
2009-07-22
Project End
2011-06-30
Budget Start
2009-07-22
Budget End
2010-06-30
Support Year
1
Fiscal Year
2009
Total Cost
$250,821
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Albacker, Lee A; Chaudhary, Vinod; Chang, Ya-Jen et al. (2013) Invariant natural killer T cells recognize a fungal glycosphingolipid that can induce airway hyperreactivity. Nat Med 19:1297-304
Chaudhary, Vinod; Albacker, Lee A; Deng, Shenglou et al. (2013) Synthesis of fungal glycolipid asperamide B and investigation of its ability to stimulate natural killer T cells. Org Lett 15:5242-5
Rachid, Rima; Umetsu, Dale T (2012) Immunological mechanisms for desensitization and tolerance in food allergy. Semin Immunopathol 34:689-702
Umetsu, Dale T; Dekruyff, Rosemarie H (2010) Natural killer T cells are important in the pathogenesis of asthma: the many pathways to asthma. J Allergy Clin Immunol 125:975-9
Lee, Hyun-Hee; Meyer, Everett H; Goya, Sho et al. (2010) Apoptotic cells activate NKT cells through T cell Ig-like mucin-like-1 resulting in airway hyperreactivity. J Immunol 185:5225-35